Health Care [ 8/12 ] | Biotechnology [ 36/76 ]
NYSE | Common Stock
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
The company was founded in 2018 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 24 | -0.15 Decreased by -66.67% | -0.06 Decreased by -150.00% |
| May 14, 24 | -0.07 Increased by +30.00% | -0.10 Increased by +30.00% |
| Feb 29, 24 | -0.06 Increased by +40.00% | -0.10 Increased by +40.00% |
| Nov 2, 23 | -0.09 Increased by +25.00% | -0.11 Increased by +18.18% |
| Aug 3, 23 | -0.09 Increased by +43.75% | -0.11 Increased by +18.18% |
| May 4, 23 | -0.10 Increased by 0.00% | -0.10 |
| Mar 15, 23 | -0.10 Increased by +16.67% | -0.11 Increased by +9.09% |
| Nov 3, 22 | -0.12 Decreased by -9.09% | -0.14 Increased by +14.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 1.44 M Increased by +N/A% | -462.49 M Decreased by -2.14 K% | Decreased by -32.23 K% Decreased by N/A% |
| Mar 31, 24 | 264.00 K Increased by +N/A% | -14.79 M Increased by +12.63% | Decreased by -5.60 K% Decreased by N/A% |
| Dec 31, 23 | 264.00 K Increased by +N/A% | -13.79 M Decreased by -85.18% | Decreased by -5.22 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Increased by +100.00% | -19.65 M Increased by +21.62% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Increased by +100.00% | -20.64 M Increased by +35.19% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -16.93 M Decreased by -17.63% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -7.45 M Increased by +70.38% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | -191.00 K Decreased by N/A% | -25.07 M Decreased by -14.05% | Increased by +13.12 K% Decreased by N/A% |